Lisa Catapano Friedman, MD
Psychiatry · Bennington, VTNPI 1619973690
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $175 of the $175 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Otsuka Pharmaceutical Development & Commercialization, Inc.. Among psychiatry clinicians in VT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1 payment — averaging $175.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$175
Across 148 payments — averaging $9407.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$753K
- Novartis$215K
- Novo Nordisk AS$210K
- Boehringer Ingelheim$134K
- Eli Lilly$50K
- E.r. Squibb & Sons, L.L.C.$17K
- plus $13K from 3 others
What the payments were for
- Consulting fees$175100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $175 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MYCITE$175
How this compares
$175 in reported general payments places this provider in the 90th percentile of 96 psychiatry providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 81 | $13,504 |
| Memantine Hcl ErMemantine Hcl | 159 | $11,866 |
| Donepezil Hcl | 918 | $8,194 |
| Bupropion XlBupropion Hcl | 15 | $2,439 |
| Tranylcypromine Sulfate | 13 | $2,050 |
| Quetiapine Fumarate | 141 | $1,363 |
| Aripiprazole | 59 | $928 |
| Escitalopram Oxalate | 98 | $830 |
| Olanzapine | 20 | $744 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $668 |
| Memantine Hcl | 42 | $586 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 17 | $441 |
| Clonazepam | 35 | $367 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 32 | $218 |
| Trazodone Hcl | 38 | $121 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Bennington
- Catherine HickeyBennington$0
- Matthew NarleskyBrattleboro$2K
- Jillan SackettShelburne$339
- David AppelBurlington$299
- John MalloyBurlington$250
- Gregoria MarreroBrattleboro$194
- Peter JacksonBurlington$132
- Matthew SommonsRutland$123
- Elizabeth JosephBrattleboro$108
- Judith TietzTownshend$97
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.